Trials / Terminated
TerminatedNCT02214628
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin®, Eylea®, or Lucentis®) During the Induction and Maintenance Phase of Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- Ophthotech Corporation · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
Detailed description
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy in either a "Simultaneous" Regimen (Fovista® administered with anti-VEGF same day) or "Pre-Treatment" Regimen (monotherapy Fovista® Day 0 followed by Fovista® administered in combination with anti-VEGF Day 2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fovista® (anti-PDGF BB) plus anti-VEGF |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2014-08-12
- Last updated
- 2024-02-23
- Results posted
- 2019-07-10
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02214628. Inclusion in this directory is not an endorsement.